拉莫三嗪可能增加心律失常风险。

Lamotrigine may Increase Risk of Arrythmias.

机构信息

Diane S. Aschenbrenner is a COVID-19 outbreak investigator for the Baltimore County Department of Health, Baltimore, MD. She also coordinates Drug Watch :

出版信息

Am J Nurs. 2021 Aug 1;121(8):23. doi: 10.1097/01.NAJ.0000767792.01749.bd.

DOI:10.1097/01.NAJ.0000767792.01749.bd

PMID:34819469

Abstract

The Food and Drug Administration (FDA) is advising health care practitioners that lamotrigine (Lamictal), used in managing seizures and bipolar disorder, may increase the risk of serious and potentially lethal arrythmias.The risk is greater if the patient has underlying cardiac disease or is taking medications that affect heart conduction.The FDA is requiring in vitro studies of other sodium channel blockers to determine if this risk is a class effect or unique to lamotrigine.

摘要

美国食品和药物管理局（FDA）提醒医疗保健从业者，用于治疗癫痫发作和双相情感障碍的拉莫三嗪（Lamictal）可能会增加严重且潜在致命心律失常的风险。如果患者有潜在的心脏疾病或正在服用影响心脏传导的药物，风险会更大。FDA 正在要求对其他钠通道阻滞剂进行体外研究，以确定这种风险是类效应还是仅存在于拉莫三嗪中。